Comparison Of Therapeutic Effects Of TAE Versus MAE Regimen In The Treatment Of Refractory And Relapsed Acute Leukemia

Background:Acute leukemia (AL) is a common malignant hematological diseases. Chemical regimen of first-line can get 60%-90% complete remission(CR), while the other patients can not achieve CR or relapsed after CR. Resistance to chemotherapeutic drugs is considered as the main cause of the refractory of acute leukemia. So we often use non-cross resistance chemotherapeutic drugs to form regimens to treat relapsed or refractory AL,The commonly used second-line chemotherapeutic regimens today are TAE (THP +cytarabine+etoposide) and MAE (mitoxantrone+cytarabine+etoposide). Our study contains 40 patients with relapsed or refractory AL, and the final report is as follows.Purpose:To compare the therapeutic effects of TAE and MAE regimen on the treatment of refractory and relapsed acute leukemia (AL) in adults.Methods:40 patients, who were diagnosed as refractory and relapsed acute leukemia were selected form Oct.2007 to June 2009, and been divided into two groups. The TAE group contains 22 patients, of which 11 were male and 12 were relapsed AL patients. 13 of them are acute myeloid leukemia (AML) patients and 9 are acute lymphocytic leukemia (ALL), and the middle age is 37(16-53); the MAE group contains 18 patients, of which 9 were male and 8 were relapsed AL patients.13 of them are acute myeloid leukemia (AML)patients and 5 are acute lymphocytic leukemia (ALL), the middle age is 38(16-60). Patients in TAE group were treated with THP combined with Ara-C and VP-16. MAE group were treated with MAE regimen:mitoxantrone (MTZ) combined with Ara-C and VP-16. The comparison of therapeutic effect and the incidence rate of side effect between groups use statistical method of Chi-Square Tests.Results:The complete remission(CR) rate of patients in the TAE group was 6/17(35.3%), the total response rate was 9/17(52.9%), and the CR rate of patients in the MAE group was 8/14(57.1%), the total response rate was 10/14(71.4%). There were no significantly statistic differences in CR rates, the total response rates and side effects in the two groups(p>0.05), but the dosage of G-CSF used in the TAE group is obviously smaller than the MAE group used, and the hospital days of MAE group is significantly longer than the TAE group(p<0.05).Conclusions:The TAE regimen is a well-effective and relatively safe treatment regimen for patients with refractory or relapsed acute leukemia (AL).